Journey Of Excellence

Rubicon has come a long way as a globally recognized drug delivery company in a short span of 13 years

2010 – Present

  • Rubicon enters into a strategic partnership with Avantor Performance Materials for further developing RubiXcip® – a specialty gastro-retentive excipient
  • Rubicon licenses out its first potential 505(b2) product to a specialty pharmaceutical company
  • Rubicon successfully delivers its first Clinical Trials Supplies (Manufacturing) for multi-centric trials for a Big Pharma
  • Rubicon receives a “preferred partner status” for developing products for a global consumer company
  • Rubicon receives UK-MHRA approval for manufacturing and packing operations
  • Rubicon licenses out a complex SR Suspension to a leading generic company
  • Rubicon successfully completes feasibility study of RubiCoat® for Big Pharma NCE project
  • Rubicon successfully completes feasibility study of RubiReten® for Big Pharma NCE project
  • Commissioned state of the art cGMP manufacturing facility in Oct 2010

2008 – 2009

  • Approval from German Health Authority (BCS) for Analytics and Stability studies
  • RubiODT® excipient licensed to Avantor Performance Materials (Formerly known as Mallinckrodt Baker Inc.) for worldwide commercialization
  • Rubicon receives MAA for Requip Equivalent for EU Market

2004 – 2007

  • Rubicon licenses out Vitamin C CR (RubiSRT®) for EU, CIS & other emerging markets
  • First International patent granted
  • Leading MNC launches Rubicon’s developed products in India
  • Rubicon licenses first CR Product i.e. Metformin CR to a US Company

2000 – 2003

  • Rubicon files its first International Patent
  • Rubicon sets up a dedicated team for technology development
  • Rubicon starts its operations with three scientists